Connect Biopharma reported multi-endpoint improvements in a Phase 3 eczema trial and said its dupilumab-like competitor achieved 52-week gains, supporting the company’s view that its approach can outperform existing options. The topline release adds momentum for Connect as the eczema market remains crowded with biologics targeting distinct inflammatory pathways. The company characterized the data as evidence of sustained clinical benefit across multiple endpoints over one year. That positioning is significant because payers and clinicians increasingly compare duration of response and endpoint breadth when differentiating therapies within the same skin disease setting. Connect’s Phase 3 update sets up further debate on comparative efficacy versus established biologics, but the core takeaway is the durability of improvements across the trial’s longer follow-up period.